Friday 6 November 2026 Export RCUS’s income statement to Excel — free account

Arcus Biosciences, Inc.

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.

Revenue: −65.4%
EPS: +21.3%
Free cash flow: +9.28%
Total debt: +4.08%

Quarter to September 2026, against a year earlier

18.39 0.70 +3.96%

Follow RCUS

Alert me

Market cap: $2.5B
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: 0/9
Altman Z: 1.11
Beneish M: −2.42
Dividend safety: n/a

Overview

Arcus Biosciences, Inc. (RCUS) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Arcus Biosciences, Inc. (RCUS) trades at a P/B ratio of 6.4×. Over the past ten years it has ranged from 0.0× (March 2018) to 11.5× (May 2020); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RCUS/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Arcus Biosciences, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RCUS/metrics/pb-ratio">Arcus Biosciences, Inc. (RCUS) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	4.1×	46.63%
FY2024	2.8×	(12.25%)
FY2023	3.2×	42.40%
FY2022	2.2×	(33.54%)
FY2021	3.3×	17.60%
FY2020	2.8×	4.83%
FY2019	2.7×	70.24%
FY2018	1.6×	—
FY2017	0.0×	—

Period	P/B ratio	Change
Sep 2026	9.2×	9.71%
Jun 2026	8.4×	62.09%
Mar 2026	5.2×	27.45%
Dec 2025	4.1×	22.10%
33 more quarters	Free account

Against its own ten years

Low 0.0× High 11.5×

Ten-year median 2.5×

Current reading's percentile 93

Company	P/B ratio
RXRX Recursion Pharmaceuticals, Inc. compare	2.1×
BEAM Beam Therapeutics Inc. compare	2.9×
IDYA IDEAYA Biosciences, Inc. compare	2.9×
NAMS NewAmsterdam Pharma Company N.V. compare	3.7×
ZLAB Zai Lab Limited Unsponsored ADR compare	4.5×
XNCR Xencor, Inc. compare	5.2×
MBX MBX Biosciences, Inc. compare	5.7×
RCUS Arcus Biosciences, Inc.	6.4×
PHVS Pharvaris N.V. compare	6.4×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Arcus Biosciences, Inc. (RCUS) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on RCUS

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on RCUS

Stockrow Weekly